Memantine Merz

Memantine, the active ingredient in Memantine Merz, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer's disease in adult patients.

GNH USA supplies Memantine Merz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and offers reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory support across multiple markets. Our dedicated technical team ensures compliance with local import requirements.

Memantine is used in the management of neurodegenerative conditions affecting cognition, primarily within the Alzheimer’s disease spectrum.

- Moderate to severe Alzheimer's disease: improves cognitive function and daily living activities when used as monotherapy or with cholinesterase inhibitors. - Mild to moderate Alzheimer's disease (adjunct): provides additional symptomatic benefit when combined with standard therapy. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression as part of comprehensive care.

Memantine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Seizures - Severe hypertension

When prescribing memantine, clinicians should consider several safety factors.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and use with caution. - History of seizures: observe for increased seizure activity. - Concomitant NMDA antagonists: avoid combined use to prevent additive toxicity. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Memantine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: may reduce memantine efficacy and increase neuropsychiatric effects. - Ketamine: additive NMDA antagonism can lead to excessive CNS depression. - Dextromethorphan: increased risk of confusion and dizziness.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may blunt cognitive benefits of memantine. - CNS depressants (e.g., benzodiazepines): enhanced sedation and dizziness. - Diuretics: possible alterations in blood pressure requiring monitoring.